Overcoming metastatic melanoma with BRAF inhibitors

Arch Pharm Res. 2011 May;34(5):699-701. doi: 10.1007/s12272-011-0521-5.

Abstract

Melanoma has the capacity to spread via the blood stream to the brain, and has been notoriously resistant to drug therapy. An activating mutation in the gene encoding BRAF is known to be responsible for half of melanomas. This article provides a review of GSK2118436 and PLX4032 as potential therapeutics for the treatment of melanomas by inhibiting oncogenic BRAF.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Drugs, Investigational / therapeutic use*
  • Humans
  • Imidazoles / therapeutic use
  • Indoles / therapeutic use
  • Melanoma / drug therapy*
  • Melanoma / secondary
  • Molecular Targeted Therapy
  • Oximes / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Skin Neoplasms / drug therapy*
  • Sulfonamides / therapeutic use
  • Vemurafenib

Substances

  • Antineoplastic Agents
  • Drugs, Investigational
  • Imidazoles
  • Indoles
  • Oximes
  • Protein Kinase Inhibitors
  • Sulfonamides
  • Vemurafenib
  • Proto-Oncogene Proteins B-raf
  • dabrafenib